分组1 - Fortune Brands Innovations reported quarterly earnings of $0.86 per share, missing the Zacks Consensus Estimate of $1 per share, and down from $0.98 per share a year ago, representing an earnings surprise of -13.86% [1][2] - The company posted revenues of $1.08 billion for the quarter, missing the Zacks Consensus Estimate by 5.29%, and down from $1.1 billion year-over-year, having topped consensus revenue estimates just once in the last four quarters [3] - The stock has gained approximately 26.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [4] 分组2 - The earnings outlook for Fortune Brands Innovations is uncertain, with current consensus EPS estimates of $0.73 on $1.05 billion in revenues for the coming quarter, and $4.03 on $4.61 billion in revenues for the current fiscal year [8] - The estimate revisions trend for the company was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [7] - The Building Products - Air Conditioner and Heating industry, to which the company belongs, is currently in the bottom 8% of Zacks industries, suggesting that the overall industry outlook may negatively impact the stock's performance [9]

分组1 - Twilio reported quarterly earnings of $1.33 per share, exceeding the Zacks Consensus Estimate of $1.24 per share, and showing an increase from $1 per share a year ago, resulting in an earnings surprise of +7.26% [1] - The company achieved revenues of $1.37 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.72%, and up from $1.19 billion year-over-year [2] - Twilio has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - Despite the positive earnings report, Twilio shares have declined approximately 22.4% since the beginning of the year, contrasting with the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.22 on revenues of $1.27 billion, and for the current fiscal year, it is $5.43 on revenues of $5.41 billion [7] 分组3 - The Zacks Industry Rank indicates that the Internet - Software sector is currently in the bottom 44% of over 250 Zacks industries, which may negatively impact Twilio's stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - Twilio currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6]

分组1 - VistaGen Therapeutics reported a quarterly loss of $0.45 per share, which was better than the Zacks Consensus Estimate of a loss of $0.51, representing an earnings surprise of +10.89% [1] - The company posted revenues of $0.3 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 43.89%, compared to revenues of $0.23 million a year ago [2] - VistaGen shares have declined approximately 13.5% since the beginning of the year, while the S&P 500 has gained 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.51 on revenues of $0.4 million, and for the current fiscal year, it is -$2.03 on revenues of $0.97 million [7] - The Medical - Biomedical and Genetics industry, to which VistaGen belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share, and down from $2.9 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was -2.34%, with the company previously expected to post earnings of $2.3 per share but actually reporting $2.26, resulting in a surprise of -1.74% [2] - Bio-Rad's revenues for the quarter were $693.2 million, slightly surpassing the Zacks Consensus Estimate by 0.01%, and up from $667.5 million year-over-year [3] - Over the last four quarters, the company has exceeded consensus revenue estimates three times [3] Stock Performance - Bio-Rad shares have declined approximately 3.1% since the beginning of the year, while the S&P 500 has gained 1.4% [4] - The current Zacks Rank for Bio-Rad is 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.79 on revenues of $605 million, and for the current fiscal year, it is $10.36 on revenues of $2.64 billion [8] - The trend of estimate revisions for Bio-Rad was mixed ahead of the earnings release, which could change following the recent report [7] Industry Context - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Agilent Technologies, another company in the same industry, is expected to report quarterly earnings of $1.37 per share, reflecting a year-over-year increase of 4.6% [10]

分组1 - SPS Commerce (SPSC) reported quarterly earnings of $1.14 per share, exceeding the Zacks Consensus Estimate of $1 per share, and up from $0.89 per share a year ago [1] - The earnings surprise for the quarter was +14.46%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenue for the quarter was $192.65 million, which missed the Zacks Consensus Estimate by 0.45%, but was an increase from $170.91 million year-over-year [3] 分组2 - The stock has underperformed, losing about 23.1% since the beginning of the year, while the S&P 500 gained 1.4% [4] - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $196.04 million, and for the current fiscal year, it is $4.52 on revenues of $806.5 million [8] - The Zacks Industry Rank for Business - Services is in the bottom 38% of over 250 Zacks industries, indicating potential challenges for stock performance [9]

分组1 - Flowers Foods reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, with an earnings surprise of +39.51% [1] - The company posted revenues of $1.23 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.09%, compared to $1.11 billion in the same quarter last year [2] - Flowers Foods has outperformed the S&P 500, gaining about 7.4% since the beginning of the year, while the S&P 500 has gained 1.4% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.32 on revenues of $1.57 billion, and for the current fiscal year, it is $1.01 on revenues of $5.24 billion [7] - The Zacks Industry Rank for Food - Miscellaneous is currently in the bottom 22% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Core Insights - Pinterest reported quarterly earnings of $0.67 per share, exceeding the Zacks Consensus Estimate of $0.66 per share, and up from $0.56 per share a year ago, representing an earnings surprise of +1.67% [1] - The company posted revenues of $1.32 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 0.73%, but an increase from $1.15 billion year-over-year [2] - Pinterest shares have declined approximately 26.3% year-to-date, contrasting with the S&P 500's gain of 1.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.25 on revenues of $982.03 million, and for the current fiscal year, it is $1.91 on revenues of $4.84 billion [7] - The estimate revisions trend for Pinterest was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Internet - Software industry, to which Pinterest belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - 10x Genomics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.19, and improved from a loss of $0.40 per share a year ago, resulting in an earnings surprise of +31.58% [1] - The company achieved revenues of $166.03 million for the quarter ended December 2025, slightly surpassing the Zacks Consensus Estimate by 0.01%, and showing a year-over-year increase from $165.02 million [2] - 10x Genomics has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance in earnings expectations [2] 分组2 - The stock has gained approximately 17.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for investors, as it reflects current consensus earnings expectations and any recent changes in those expectations [4] - The estimate revisions trend for 10x Genomics was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] 分组3 - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $142.23 million, and for the current fiscal year, it is -$0.88 on revenues of $609.12 million [7] - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Research Solutions Inc. (RSSS) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.03, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Research Solutions, which belong ...

Core Viewpoint - Trupanion reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.14 per share, but showing an increase from $0.04 per share a year ago [1][2] Earnings Performance - The earnings surprise for the quarter was -9.72%, while the previous quarter saw a positive surprise of +116.67% when actual earnings were $0.13 compared to an expected $0.06 [2] - Over the last four quarters, Trupanion has surpassed consensus EPS estimates three times [2] Revenue Performance - Trupanion's revenues for the quarter ended December 2025 were $376.85 million, exceeding the Zacks Consensus Estimate by 0.28% and up from $337.31 million year-over-year [3] - The company has topped consensus revenue estimates four times over the last four quarters [3] Stock Performance and Outlook - Trupanion shares have declined approximately 13.5% since the beginning of the year, contrasting with the S&P 500's gain of 1.4% [4] - The future performance of the stock will largely depend on management's commentary during the earnings call [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $377.47 million, and for the current fiscal year, it is $0.51 on revenues of $1.58 billion [8] - The estimate revisions trend for Trupanion was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [7] Industry Context - The Insurance - Accident and Health industry, to which Trupanion belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [9]